 |
|
|
| |
Antiviral activity, exposure-response, and resistance analyses of monotherapy with the novel HIV nucleoside reverse transcriptase inhibitor
(NRTI) BMS-986001 in antiretroviral treatment-experienced subjects
|
| |
| |
Reported by Jules Levin
13th International Workshop on Clinical Pharmacology of HIV Therapy
16-18 April 2012, Barcelona, Spain
C Hwang,1 L Zhu,1 HM Chan,1 I Chang,1 GJ Hanna,1 R Bertz,1 D Grasela1
1Bristol-Myers Squibb, Research and Development, Princeton, NJ, USA
|
| |
|
|
|
|
|
